Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for RaQualia Pharma Inc. (4579:JPX), powered by AI.
RaQualia Pharma Inc. is currently trading at ¥469. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for RaQualia Pharma Inc. on Alpha Lenz.
View RaQualia Pharma Inc.'s valuation metrics on Alpha Lenz.
“RaQualia Pharma Inc.'s ROE is 4.4%. Explore profitability and growth together.”
Ask for details →RaQualia Pharma Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel pharmaceuticals. With a primary focus on therapeutic areas such as pain management, oncology, and gastrointestinal diseases, RaQualia aims to address unmet medical needs through innovative drug discovery and development processes. The company utilizes cutting-edge technologies and proprietary platforms to advance its pipeline of drug candidates, contributing to the improvement of health and wellbeing globally. Operating within the highly dynamic pharmaceutical sector, RaQualia Pharma Inc. plays a pivotal role by collaborating with academic institutions, strategic partners, and industry entities to drive its projects from preclinical stages to clinical trials, ultimately aiming for market approval. Positioned in the competitive pharmaceutical marketplace, RaQualia continues to leverage its expertise in medicinal chemistry and pharmacology to emerge as a key player in the development of effective treatment solutions.
“RaQualia Pharma Inc.'s ROE is 4.4%. Explore profitability and growth together.”
Ask for details →RaQualia Pharma Inc. (ticker: 4579) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 64 employees.
The current price is 469 with a P/E ratio of -x and P/B of -x.
ROE is 4.38% and operating margin is 12.15%. Annual revenue is $4.0B.